RANKL Blocking Peptide
RANKL Blocking Peptide
Product No.: R1243
- -
- -
Target sRANKL Product Type Blocking Peptide Alternate Names CD254, TRANCE, hRANKL2, sOdf, TNF-Related Activation-Induced Cytokine [TRANCE], Osteoprotegrin Ligand [OPGL], Osteoclast Differentiation Factor [ODF], TNFSF11 |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Product Concentration 0.2 mg/ml Amino Acid Location 14 amino acids near the center of human sRANK-L. Formulation This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide. Storage and Handling Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day Ambient Amino Acid Sequence 14 amino acids near the center of human sRANK-L. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. Background RANKL (Receptor Activator for Nuclear Factor κ B Ligand), also known as TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and ODF (osteoclast differentiation factor), is a member of the tumor necrosis factor family cytokine.1 RANKL is essential for osteoclast formation, activation, and survival.2 RANKL through interaction with its receptor RANK can modulate matrix degradation and inflammation.3 RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy. Consequently, novel drugs specifically targeting RANK, RANKL, and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various ailments associated with bone loss, such as arthritis, periodontal disease, cancer metastases, and osteoporosis.4 Antigen DetailsReferences & Citations1. H Takayanagi et al. (2003) Arthritis Res Ther. 5: 20
2. Kostenuik PJ et al. (2005) Endocrinology 146: 3235
3. Holven KB et al. (2009) Stroke 40: 241
4. Penninger JM et al. (2008) Ann N Y Acad Sci. 1143: 123 |
Related Products
- -
- -
Prod No. | Description |
---|---|
R1243 | |
R139 | |
R1145 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.